Second, we identified significantly higher levels of circulating IL-22+Th1 cells in responders than in HC at the baseline level and these cells decreased after treatment in responsive RA patients, suggesting that up-regulated IL-22+Th1 cell levels may contribute the pathogenesis of RA and they may participate in response to MTX+LEF treatment. The gene discussed is IL22; the disease is rheumatoid arthritis.